Anna Nordmark

950 total citations
22 papers, 733 citations indexed

About

Anna Nordmark is a scholar working on Pediatrics, Perinatology and Child Health, Pharmacology and Oncology. According to data from OpenAlex, Anna Nordmark has authored 22 papers receiving a total of 733 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pediatrics, Perinatology and Child Health, 11 papers in Pharmacology and 7 papers in Oncology. Recurrent topics in Anna Nordmark's work include Pharmacogenetics and Drug Metabolism (10 papers), Drug Transport and Resistance Mechanisms (7 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Anna Nordmark is often cited by papers focused on Pharmacogenetics and Drug Metabolism (10 papers), Drug Transport and Resistance Mechanisms (7 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Anna Nordmark collaborates with scholars based in Sweden, United States and United Kingdom. Anna Nordmark's co-authors include Anders Rane, Susan Cole, Eva Gil Berglund, Stefan Lundgren, Carolien Versantvoort, Kevin Blake, Leif Bertilsson, Roberto Canaparo, Niklas Finnström and Anders Lindahl and has published in prestigious journals such as Fertility and Sterility, Obstetrics and Gynecology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Anna Nordmark

22 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Nordmark Sweden 15 247 192 138 137 135 22 733
Punit H. Marathe United States 15 158 0.6× 220 1.1× 96 0.7× 246 1.8× 182 1.3× 31 854
Achiel Van Peer Belgium 19 319 1.3× 202 1.1× 202 1.5× 208 1.5× 123 0.9× 43 1.2k
Jennifer E. Sager United States 10 325 1.3× 167 0.9× 149 1.1× 155 1.1× 54 0.4× 19 826
Barbara Schug Germany 16 112 0.5× 73 0.4× 146 1.1× 151 1.1× 272 2.0× 47 991
P. Marathe United States 12 253 1.0× 360 1.9× 211 1.5× 162 1.2× 92 0.7× 19 745
Susan Cole United Kingdom 14 290 1.2× 268 1.4× 150 1.1× 276 2.0× 42 0.3× 28 916
Venkatesh Pilla Reddy United States 19 207 0.8× 305 1.6× 130 0.9× 325 2.4× 28 0.2× 56 1.1k
François Bouzom France 15 215 0.9× 229 1.2× 186 1.3× 224 1.6× 55 0.4× 24 823
Adriaan Cleton United States 19 88 0.4× 121 0.6× 126 0.9× 213 1.6× 60 0.4× 58 978
David L. Bourdet United States 14 194 0.8× 317 1.7× 160 1.2× 182 1.3× 82 0.6× 37 821

Countries citing papers authored by Anna Nordmark

Since Specialization
Citations

This map shows the geographic impact of Anna Nordmark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Nordmark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Nordmark more than expected).

Fields of papers citing papers by Anna Nordmark

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Nordmark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Nordmark. The network helps show where Anna Nordmark may publish in the future.

Co-authorship network of co-authors of Anna Nordmark

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Nordmark. A scholar is included among the top collaborators of Anna Nordmark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Nordmark. Anna Nordmark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ritchie, Tasha K., Jingjing Yu, Anna Nordmark, et al.. (2020). Inhibitors of Organic Anion‐Transporting Polypeptides 1B1 and 1B3: Clinical Relevance and Regulatory Perspective. The Journal of Clinical Pharmacology. 60(8). 1087–1098. 4 indexed citations
2.
Ritchie, Tasha K., et al.. (2019). Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3. Clinical and Translational Science. 12(4). 379–387. 18 indexed citations
3.
Ritchie, Tasha K., et al.. (2018). Identification and evaluation of clinical substrates of organic anion transporting polypeptides 1B1 and 1B3. Drug Metabolism and Pharmacokinetics. 33(1). S19–S19. 1 indexed citations
4.
Suarez‐Sharp, Sandra, Michael R. Cohen, Filippos Kesisoglou, et al.. (2018). Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report. The AAPS Journal. 20(6). 93–93. 61 indexed citations
5.
Lennernäs, Hans, Anders Lindahl, A. Van Peer, et al.. (2017). In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context. Molecular Pharmaceutics. 14(4). 1307–1314. 44 indexed citations
6.
Blake, Kevin, et al.. (2016). Physiologically based pharmacokinetic modeling in regulatory decision‐making at the European Medicines Agency. Clinical Pharmacology & Therapeutics. 102(1). 98–105. 105 indexed citations
7.
Scott, Graham, et al.. (2015). Physiologically Based Models in Regulatory Submissions: Output From the ABPI/MHRA Forum on Physiologically Based Modeling and Simulation. CPT Pharmacometrics & Systems Pharmacology. 4(4). 221–225. 52 indexed citations
8.
Hsu, Vicky, Manuela de Lima Toccafondo Vieira, Ping Zhao, et al.. (2013). Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations. Clinical Pharmacokinetics. 53(3). 283–293. 77 indexed citations
9.
Nordmark, Anna, et al.. (2013). Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data. European Journal of Clinical Pharmacology. 70(2). 167–178. 15 indexed citations
10.
Raboisson, Patrick, Anna Breitholtz‐Emanuelsson, Louise Edwards, et al.. (2012). Discovery and characterization of AZD9272 and AZD6538—Two novel mGluR5 negative allosteric modulators selected for clinical development. Bioorganic & Medicinal Chemistry Letters. 22(22). 6974–6979. 29 indexed citations
11.
12.
Canaparo, Roberto, Niklas Finnström, Loredana Serpe, et al.. (2007). EXPRESSION OF CYP3A ISOFORMS AND P‐GLYCOPROTEIN IN HUMAN STOMACH, JEJUNUM AND ILEUM. Clinical and Experimental Pharmacology and Physiology. 34(11). 1138–1144. 73 indexed citations
13.
Wennerholm, Agneta, et al.. (2006). Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. European Journal of Clinical Pharmacology. 62(7). 539–546. 22 indexed citations
14.
Söderström, T., et al.. (2006). Association of cytochrome P450 1B1 polymorphism with first-trimester miscarriage. Fertility and Sterility. 86(5). 1498–1503. 9 indexed citations
15.
Canaparo, Roberto, Anna Nordmark, Niklas Finnström, et al.. (2006). Expression of Cytochromes P450 3A and P‐Glycoprotein in Human Large Intestinse in Paired Tumour and Normal Samples. Basic & Clinical Pharmacology & Toxicology. 100(4). 240–248. 25 indexed citations
16.
Härtter, Sebastian, Anna Nordmark, Dirk‐Matthias Rose, et al.. (2003). Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. British Journal of Clinical Pharmacology. 56(6). 679–682. 59 indexed citations
17.
Granhall, Charlotte, Anna Nordmark, Arkadiusz Orzechowski, et al.. (2002). Characterization of testosterone metabolism and 7-hydroxycoumarin conjugation by rat and human liver slices after storage in liquid nitrogen for 1 h up to 6 months. Xenobiotica. 32(11). 985–996. 6 indexed citations
18.
Nordmark, Anna, et al.. (2002). The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. British Journal of Clinical Pharmacology. 54(5). 504–510. 47 indexed citations
19.
Clausson, Britt, Fredrik Granath, Anders Ekbom, et al.. (2002). Effect of Caffeine Exposure During Pregnancy on Birth Weight and Gestational Age. Obstetrical & Gynecological Survey. 57(8). 481–482. 3 indexed citations
20.
Nordmark, Anna, Stefan Lundgren, Sven Cnattingius, & Anders Rane. (1999). Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. British Journal of Clinical Pharmacology. 47(4). 397–402. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Punit H. Marathe Breakdown of academic impact, for papers by Achiel Van Peer Breakdown of academic impact, for papers by Jennifer E. Sager Breakdown of academic impact, for papers by Barbara Schug Breakdown of academic impact, for papers by P. Marathe Breakdown of academic impact, for papers by Susan Cole Breakdown of academic impact, for papers by Venkatesh Pilla Reddy Breakdown of academic impact, for papers by François Bouzom Breakdown of academic impact, for papers by Adriaan Cleton Breakdown of academic impact, for papers by David L. Bourdet
Rankless by CCL
2026